STL303 not checked

Sitala Bio LTD

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“STL303 arm participants will receive a specific dose of STL303”In the company’s words, NCT07606352 on ClinicalTrials.gov
Tested for
IgAN, Geographic Atrophy
Main trialPhase 2
“This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of STL303 capsules in IgAN patients. About 15 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of STL303 or placebo capsules orally according to protocol.”In the company’s words, NCT07606352 on ClinicalTrials.gov

Other drugs for IgAN

All 39 drugs for IgAN

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Jul 2027 Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy
Phase 2Recruiting Jul 2028 A Study in Adults With Geographic Atrophy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow STL303

Following is part of Solo: you see every change to STL303 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in